We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion
Read MoreHide Full Article
Roche (RHHBY - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended label expansion of the hemophilia A drug Hemlibra (emicizumab) in the European Union (EU).
The CHMP recommended Hemlibra for the routine prophylaxis of bleeding episodes in people with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease with a severe bleeding phenotype.
Hemlibra is a bispecific factor IXa- and factor X-directed antibody.
Per estimates, people with moderate hemophilia A make up 14% of the hemophilia A population. Hemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. A final decision from the European Commission is expected shortly.
The positive recommendation is based on the results from the phase III HAVEN-6 study as well as on real-world data. The results from the study showed that Hemlibra demonstrated effective bleed control and a favorable safety profile in people with non-severe hemophilia A without factor VIII inhibitors, where prophylaxis was clinically indicated.
We remind investors that Hemlibra is already approved in many countries as a treatment for people with hemophilia A with factor VIII inhibitors and for people without factor VIII inhibitors.
The label expansion of the drug in the EU will provide an effective and convenient prophylactic treatment option with a favorable safety profile for people with moderate hemophilia A with a severe bleeding phenotype.
Shares of Roche have declined 22% in the year so far against the industry’s increase of 11%.
Image Source: Zacks Investment Research
The label expansion of Hemlibra will strengthen Roche’s strong hematology portfolio, which includes approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvaro (obinutuzumab), Polivy (polatuzumab vedotin), Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Hemlibra (emicizumab) and Lunsumio (mosunetuzumab). The pipeline of investigational hematology medicines includes T-cell-engaging bispecific antibodies glofitamab, targeting both CD20 and CD3, and cevostamab, targeting both FcRH5 and CD3; Tecentriq (atezolizumab), a monoclonal antibody designed to bind with PD-L1 and crovalimab, an anti-C5 antibody engineered to optimize complement inhibition.
Strong demand for new drugs, namely Hemlibra, Ocrevus (multiple sclerosis), Evrysdi (spinal muscular atrophy), Phesgo (cancer) and Tecentriq (cancer), maintains momentum for the company and offsets stiff competition from biosimilars for some of Roche’s key drugs, such as Avastin, MabThera/Rituxan and Herceptin.
Earnings estimates for Sanofi have increased 6 cents in the last 90 days to $4.16. Sanofi has surpassed earnings estimates in all of the past four quarters with an average positive beat of 9.50%.
Earnings estimates for Gilead Sciences have increased 48 cents in the last 60 days to $7.09. Gilead has surpassed earnings estimates in three of the past four quarters with an average positive beat of 0.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion
Roche (RHHBY - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended label expansion of the hemophilia A drug Hemlibra (emicizumab) in the European Union (EU).
The CHMP recommended Hemlibra for the routine prophylaxis of bleeding episodes in people with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease with a severe bleeding phenotype.
Hemlibra is a bispecific factor IXa- and factor X-directed antibody.
Roche Holding AG Price and Consensus
Roche Holding AG price-consensus-chart | Roche Holding AG Quote
Per estimates, people with moderate hemophilia A make up 14% of the hemophilia A population. Hemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. A final decision from the European Commission is expected shortly.
The positive recommendation is based on the results from the phase III HAVEN-6 study as well as on real-world data. The results from the study showed that Hemlibra demonstrated effective bleed control and a favorable safety profile in people with non-severe hemophilia A without factor VIII inhibitors, where prophylaxis was clinically indicated.
We remind investors that Hemlibra is already approved in many countries as a treatment for people with hemophilia A with factor VIII inhibitors and for people without factor VIII inhibitors.
The label expansion of the drug in the EU will provide an effective and convenient prophylactic treatment option with a favorable safety profile for people with moderate hemophilia A with a severe bleeding phenotype.
Shares of Roche have declined 22% in the year so far against the industry’s increase of 11%.
Image Source: Zacks Investment Research
The label expansion of Hemlibra will strengthen Roche’s strong hematology portfolio, which includes approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvaro (obinutuzumab), Polivy (polatuzumab vedotin), Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Hemlibra (emicizumab) and Lunsumio (mosunetuzumab). The pipeline of investigational hematology medicines includes T-cell-engaging bispecific antibodies glofitamab, targeting both CD20 and CD3, and cevostamab, targeting both FcRH5 and CD3; Tecentriq (atezolizumab), a monoclonal antibody designed to bind with PD-L1 and crovalimab, an anti-C5 antibody engineered to optimize complement inhibition.
Strong demand for new drugs, namely Hemlibra, Ocrevus (multiple sclerosis), Evrysdi (spinal muscular atrophy), Phesgo (cancer) and Tecentriq (cancer), maintains momentum for the company and offsets stiff competition from biosimilars for some of Roche’s key drugs, such as Avastin, MabThera/Rituxan and Herceptin.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Sanofi (SNY - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) . Both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings estimates for Sanofi have increased 6 cents in the last 90 days to $4.16. Sanofi has surpassed earnings estimates in all of the past four quarters with an average positive beat of 9.50%.
Earnings estimates for Gilead Sciences have increased 48 cents in the last 60 days to $7.09. Gilead has surpassed earnings estimates in three of the past four quarters with an average positive beat of 0.36%.